ReviewAmerican journal of translational research2025
Efficacy and safety of traditional Chinese medicine for endometriosis-related pain: a meta-analysis.
Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing the frontiers of phytotherapy: a comprehensive review of botanical interventions targeting mitochondrial quality control to ameliorate endometriosis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate the efficacy and safety of Chinese herbal medicine (CHM) for endometriosis-associated pain (EAP).
methodsRandomized controlled trials (RCTs) were retrieved from PubMed, Embase, and Cochrane Library up to July 2025. The intervention group received CHM alone, while controls received placebo, western medicine, or no treatment. Primary outcomes included pain relief measured by the visual analog scale (VAS) for dysmenorrhea, dyspareunia, and pelvic pain, as well as adverse reactions. Secondary outcomes were TNF-α and IL-6 levels. The risk of bias was assessed using Cochrane RoB 2.0, and data were analyzed using RevMan 5.4.
resultsEleven RCTs (1401 participants) were included. CHM significantly reduced VAS scores for dysmenorrhea (SMD=-2.04, P=0.0484) and dyspareunia (SMD=-2.42, P=0.0031), although heterogeneity was high. No significant effect was observed on pelvic pain (SMD=-1.70, P=0.0793). CHM significantly decreased serum TNF-α (SMD=-0.85, P<0.0001) and IL-6 (SMD=-0.77, P<0.0001, I
conclusionCHM effectively relieves EAP-related dysmenorrhea and dyspareunia, and reduces TNF-α/IL-6, with acceptable safety. However, its effect on pelvic pain remains inconclusive. Further high-quality RCTs with standardized interventions are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.